Lupin Receives US FDA Tentative Approval for Apixaban Oral Suspension
By United One News · AI-generated summary of 1 outlets' reporting
Published
AI-generated summary of the coverage listed below:
- Lupin Limited announced on Monday, September 28, 2026, that it received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL.
- The product is an oral liquid formulation of apixaban, the active ingredient also found in Eliquis.
Covered by 1 outlet across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Lupin Receives US FDA Tentative Approval For Apixaban Oral Suspension 1.25mg/mL
Timeline
First reported by Free Press Journal on ; 1 article from 1 outlets so far.
Who is covering this story
- Center (1): Free Press Journal